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Biphasic expression of stromal cell-derived 
factor-1 during human wound healing
Chemokines such as 
SDF-1/CXCL12 not 
only regulate the dis-
tribution of invading 
leucocytes but also 
control tissue remod-
elling. Employing in 
situ hybridization, 
Toksoy et al. studied 
SDF-1/CXCL12 expression after artificial wounding of human 
skin. While it was evenly expressed by endothelial cells and 
fibroblasts in undisturbed skin, a remarkable spatial pattern 
became obvious after injury: SDF-1/CXCL12 was upregulated 
at the wound margins whereas it was completely suppressed 
in the fibrous neostroma that replaced the provisional matrix 
covering the initial wound defect. Altogether, the data sug-
gest that SDF-1/CXCL12 exerts multiple functions during 
wound repair that include regulation of neoangiogenesis, 
fibroblast proliferation and epithelialization. Br J Dermatol 
2007; 157:1148–84.
The role of filaggrin null alleles in hand 
eczema and contact allergy
Carriers of one of the variant filaggrin alleles strongly asso-
ciated with atopic dermatitis, R501X and 2282del4, have 
varying degrees of impaired skin barrier. Genetic risk fac-
tors influence the risk of hand eczema, and an impaired skin 
barrier facilitates the penetration of contact allergens. Thus, 
a possible role of the variant alleles in the pathogenesis of 
hand eczema and contact allergy could be hypothesized. 
However, in this genetic-epidemiological study no associa-
tion between the variant filaggrin alleles and hand eczema or 
contact allergy could be demonstrated. Br J Dermatol 2007; 
157:1199–204.
MC1R genotype influences erythemal 
sensitivity to PUVA
Psoralen–ultraviolet A (PUVA) photochemotherapy is widely 
used to treat psoriasis and other common skin diseases. There 
are unpredictable interindividual differences in the acute ery-
themal effects of PUVA and its longer-term risk of skin cancer. 
Polymorphisms in the melanocortin 1 receptor (MC1R) have 
been associated with increased sensitivity to UV radiation 
and skin cancer risk. Smith et al. studied MC1R genotype in 
patients commencing PUVA and found that inheritance of the 
Val60Leu, Arg163Gln and multiple MC1R SNPs was associated 
with increased erythemal sensitivity. These data suggest that 
MC1R genotype influences PUVA sensitivity and increase 
our understanding of genetic factors that predict photoche-
motherapy responses. Br J Dermatol 2007; 157:1230–4.
The applicability and prognostic value of the 
new TNM classification system for primary 
cutaneous lymphomas other than mycosis 
fungoides and Sézary syndrome
Research in primary cutane-
ous lymphomas (PCL) has been 
hampered by inconsistent classi-
fications and lack of a consistent 
system to define disease extent. 
Recently, a TNM classification 
for PCL other than mycosis fun-
goides and Sézary syndrome 
was proposed for consistent 
reporting of disease extent. Senff 
et al. tested the applicability 
and prognostic significance of 
this TNM classification on 300 
patients with an indolent or 
aggressive type of cutaneous B-
cell lymphoma, as recognized in the WHO–EORTC classifi-
cation. The TNM system was found to be useful in document-
ing disease extent and showed prognostic significance in the 
aggressive, but not in the indolent, subgroups. Br J Dermatol 
2007; 157:1205–11.
Isotretinoin therapy and the incidence of acne 
relapse
Isotretinoin is an effective treatment for severe nodular acne. 
However, data regarding its long-term benefits are lacking. 
Using a population-based cohort of 17 351 first-time isotret-
inoin users followed for up to 20 years, Azoulay et al. found 
that 41% of subjects experienced an acne relapse neces-
sitating further treatment with an antiacne agent (isotreti-
noin or other). The authors also identified several predic-
tors of experiencing an acne relapse. Thus, in view of iso-
tretinoin’s relatively 
high relapse rate 
and important side-
effects profile, these 
data could be of 
prognostic value to 
clinicians who treat 
patients with acne. 
Br J Dermatol 2007; 
157:1240–8.
